GlassScriptPhysician profile
Christopher Bondoc
NPI 1528555117
$7,131.55
in general payments reported to CMS, 2019-2025
45 companies · $2,985 in 2025
The $2,985 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.84 · 2023: $849 · 2024: $3,284 · 2025: $2,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,117.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,736.30 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Lundbeck LLC | $458.81 | 2023-2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $414.07 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $409.38 | 2024-2025 | Hyqvia |
| Neurocrine Biosciences, INC. | $399.69 | 2023-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $379.32 | 2025 | Symbravo, Auvelity |
| Harmony Biosciences LLC | $316.90 | 2023-2025 | Wakix |
| Pfizer INC. | $292.96 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $289.91 | 2023-2025 | Rytary, Crexont |
| Medtronic, INC. | $247.04 | 2024 | Percept PC Brainsense |
| Grifols USA, LLC | $208.20 | 2023-2025 | Gamunex-C |
| Argenx US, INC. | $202.54 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $152.92 | 2023-2025 | Rystiggo, Briviact, Zilbrysq |
| Jazz Pharmaceuticals INC. | $130.74 | 2023-2024 | |
| Sk Life Science, INC. | $119.71 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $106.58 | 2024-2025 | Dysport |
| Kyowa Kirin, INC. | $103.05 | 2023-2024 | Nourianz |
| Alexion Pharmaceuticals, INC. | $92.01 | 2023-2025 | Ultomiris, Soliris |
| Inspire Medical Systems, INC. | $86.21 | 2024-2025 | Inspire |
| Octapharma USA, INC. | $85.89 | 2024 | Panzyga |
| Zoll Respicardia, INC. | $69.60 | 2024 | Remede System |
| Catalyst Pharmaceuticals, INC. | $64.30 | 2023-2025 | Fycompa |
| Genentech USA, INC. | $63.47 | 2025 | Ocrevus Zunovo |
| Eisai INC. | $63.13 | 2024-2025 | |
| Tanabe Pharma America, INC. | $57.20 | 2024-2025 | Radicava |
| Protega Pharmaceutials INC | $52.08 | 2024 | Roxybond |
| Alnylam Pharmaceuticals INC. | $51.19 | 2024 | Amvuttra |
| Lilly USA, LLC | $50.00 | 2023 | Emgality |
| Scilex Pharmaceuticals INC. | $48.01 | 2024 | |
| Tonix Medicines, INC. | $36.04 | 2025 | Zembrace Symtouch |
| Otsuka America Pharmaceutical, INC. | $34.82 | 2024 | Nuedexta |
| Genzyme Corporation | $31.92 | 2025 | |
| Acadia Pharmaceuticals INC | $29.51 | 2023-2024 | Nuplazid |
| Ge Healthcare | $29.24 | 2025 | |
| Biogen, INC. | $28.38 | 2025 | Leqembi |
| Abbott Laboratories | $24.60 | 2025 | Infinity |
| Impel Pharmaceuticals LLC | $20.44 | 2025 | Trudhesa |
| Amgen INC. | $20.33 | 2024 | Uplizna |
| Vanda Pharmaceuticals INC. | $20.31 | 2025 | Ponvory |
| Vertex Pharmaceuticals Incorporated | $20.30 | 2025 | |
| Amylyx Pharmaceuticals, INC. | $20.20 | 2024 | Relyvrio |
| Microtransponder, INC. | $19.06 | 2024 | |
| Emd Serono, INC. | $17.23 | 2023 | Mavenclad |
| Acorda Therapeutics, INC | $14.75 | 2024 | Inbrija |
| Astrazeneca Pharmaceuticals LP | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bondoc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.